Cargando…

Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression

OBJECTIVE: Preclinical evidence indicates that rapid changes in levels of allopregnanolone, the predominant metabolite of progesterone, confer dramatic behavioral changes and may trigger postpartum depression (PPD) in some women. Considering the pathophysiology of PPD (i.e., triggered by reproductiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanes, Stephen J., Colquhoun, Helen, Doherty, James, Raines, Shane, Hoffmann, Ethan, Rubinow, David R., Meltzer‐Brody, Samantha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396368/ https://www.ncbi.nlm.nih.gov/pubmed/28370307 http://dx.doi.org/10.1002/hup.2576

Ejemplares similares

Brexanolone as adjunctive therapy in super‐refractory status epilepticus
por: Rosenthal, Eric S., et al.
Publicado: (2017)

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making
por: Gerbasi, Margaret E., et al.
Publicado: (2021)

Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
por: Garafola, Svetlana, et al.
Publicado: (2023)

Efficacy of brexanolone in postpartum depression
por: Rodríguez Mercado, C. M.
Publicado: (2023)

Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
por: Meltzer-Brody, Samantha, et al.
Publicado: (2020)

Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States
por: Eldar-Lissai, Adi, et al.
Publicado: (2020)

Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’
por: Shukla, Ajay Kumar, et al.
Publicado: (2021)

Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways
por: Balan, Irina, et al.
Publicado: (2023)

Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose
por: Wald, Jeffrey, et al.
Publicado: (2022)

SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
por: Hoffmann, Ethan, et al.
Publicado: (2019)

Treating Postpartum Depression: What Do We Know about Brexanolone?
por: Ali, Muneeza, et al.
Publicado: (2021)

Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
por: Faden, Justin, et al.
Publicado: (2020)

Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis
por: Salwan, Aaron, et al.
Publicado: (2023)

Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy
por: Reddy, Doodipala Samba, et al.
Publicado: (2023)

Brexanolone, a GABA(A) Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression
por: Rudzinskas, Sarah A., et al.
Publicado: (2023)

Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021)

Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression
por: Gerbasi, Margaret E., et al.
Publicado: (2020)

New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum
por: Meltzer-Brody, Samantha
Publicado: (2011)

Transcriptome-wide association study for postpartum depression implicates altered B-cell activation and insulin resistance
por: Guintivano, Jerry, et al.
Publicado: (2022)

Structured physical exercise for bipolar depression: an open-label, proof-of concept study
por: Lafer, Beny, et al.
Publicado: (2023)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Feasibility and proof of concept of a proprietary non-contact ablation system with low intensity collimated ultrasound
por: Leshem-Rubinow, E, et al.
Publicado: (2023)

Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression
por: Cooper, Miranda C., et al.
Publicado: (2019)

Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study
por: Sharma, Alok, et al.
Publicado: (2013)

Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience
por: Lüscher, Bernhard, et al.
Publicado: (2019)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
por: Perkins, Bruce A., et al.
Publicado: (2015)

A Dedicated Postpartum Intrauterine Device Inserter: Pilot Experience and Proof of Concept
por: Singh, Sharad, et al.
Publicado: (2016)

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
por: MACHADO-VIEIRA, RODRIGO, et al.
Publicado: (2014)

An open-label proof-of-concept study of intrathecal autologous bone marrow mononuclear cell transplantation in intellectual disability
por: Sharma, Alok, et al.
Publicado: (2018)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
por: Jang, Jun Ho, et al.
Publicado: (2022)

Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention
por: Sylvia, Louisa G, et al.
Publicado: (2013)

Virtual patient educational programme to teach counselling to clinical pharmacists: development and proof of concept
por: Richardson, Charlotte Lucy, et al.
Publicado: (2018)

Point-of-care testing to promote cardiovascular disease risk assessment: A proof of concept study
por: Karmali, Kunal N., et al.
Publicado: (2017)

Frequency of Sperm Aneuploidy in Oligoasthenoteratozoospermic (OAT) Patients by Comprehensive Chromosome Screening: A Proof of Concept
por: Saei, Parishad, et al.
Publicado: (2021)

Diagnosis of SARS-CoV-2 infection from breath - a proof-of-concept study
por: Katende, Bulemba, et al.
Publicado: (2022)

App-Based Ecological Momentary Assessment to Enhance Clinical Care for Postpartum Depression: Pilot Acceptability Study
por: Krohn, Holly, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_apsbc7arh3hu5a8nr4v45j9bs8